CALC · XBRL financial data

CalciMedica financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CALC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development2,7722,782*2,9444,1573,5463,831*4,2244,0523,8513,107*3,4852,102
General and administrative2,0611,537*2,8232,3722,1902,341*2,2732,5691,7671,278*2,1261,910
Total operating expenses4,8334,319*5,7676,5295,7366,172*6,4976,6215,6184,385*5,6114,012
Operating income (loss)(4,833)(4,319)*(5,767)(6,529)(5,736)(6,172)*(6,497)(6,621)(5,618)(4,385)*(5,611)(4,012)
Interest expense——0000*447324326325*319325
Other income (expense)214283*307275218214*—2690(1)*—231
Income tax expense (benefit)01*0000*0000*00
Net income (loss)(4,619)(4,146)*130(3,954)(5,618)(4,258)*(5,042)(5,956)(7,804)(10,760)*4,976(7,652)
Earnings per share, basic USD per share(0.82)—0.01(0.36)(0.50)(0.33)*(0.36)(0.40)(0.52)(0.68)*0.31(0.45)
Earnings per share, diluted USD per share(0.82)—0.01(0.36)(0.50)(0.34)*(0.36)(0.40)(0.52)(0.68)*0.30(0.45)
Weighted average shares, basic thousands of shares5,667—9,75511,12911,13512,948*14,12214,99515,07615,832*15,82217,100
Weighted average shares, diluted thousands of shares5,667—10,04711,12911,13512,658*14,12214,99515,07615,832*16,32917,100

Balance sheet

CSV

Fiscal quarters (CALC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents11,6445,5306,7555,0569,1517,93512,5565,9185,47011,5208,16418,617
Short-term investments2,9475,70818,95514,0815,45210,73412,06912,0398,6141,49600
Prepaid and other current assets6823678941,3051,083248197655539259122575
Total current assets15,27311,60526,60420,44215,68619,66525,21818,96414,85313,5308,55519,463
Property and equipment, net18716715313813011911810549504336
Right-of-use asset00——————————
Total assets15,84512,18527,13421,05216,21219,79425,34719,08014,91313,5918,60919,503
Accounts payable1,4171,4191,5352,1441,5361,9982,0161,9121,1331,1611,6752,073
Total current liabilities3,6864,0284,2873,9143,7823,6844,4593,4773,6813,7825,3133,490
Total liabilities3,6864,0289,8877,2147,1825,38414,45912,97715,18120,2329,71313,990
Accumulated deficit(141,918)(146,064)(145,934)(149,888)(155,506)(159,764)(164,806)(170,762)(178,566)(189,326)(184,350)(192,002)
Total stockholders' equity12,1598,15717,24713,8389,03014,41010,8886,103(268)(6,641)(1,104)5,513
Total liabilities and equity15,84512,18527,13421,05216,21219,79425,34719,08014,91313,5918,60919,503
Common shares outstanding (cover page) thousands of shares5,68510,74010,74910,75013,48213,48213,97213,97214,25715,74415,79834,141

Cash flows

CSV

Fiscal quarters (CALC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(4,619)(4,146)*130(3,954)(5,618)(4,258)*(5,042)(5,956)(7,804)(10,760)*4,976(7,652)
Stock-based compensation482*(32)*414486*781*632*5491,175*625*622*561540*
Depreciation and amortization12*19*——————————
Net cash from operating activities(4,571)*(3,612)*(4,715)(6,792)*(4,667)*(4,972)*(4,878)(6,670)*(4,778)*(4,852)*(4,856)(4,620)*
Purchases of property and equipment0*0*00*6*2*95*8*6*00*
Net cash from investing activities(2,941)*(2,677)*(13,103)5,100*8,747*(5,167)*(1,243)134*3,512*7,148*1,50042*
Proceeds from issuing common stock0*0*19,043(60)*0*8,922*80*0*0*012,000*
Net cash from financing activities72*175*19,043(7)*16*8,922*10,742(102)*818*3,754*015,031*
Net change in cash(7,440)*(6,114)*1,225(1,699)*4,096*(1,217)*4,621(6,638)*(448)*6,050*(3,356)10,453*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
CalciMedica18,617not reported(4,620)*34.1M4.0 quarters 10-QJun 30, 2026
Pluri3,529335*(4,443)*12.3M0.8 quarters 10-KJun 30, 2026
ProPhase Labs201,011(78)*15.6M0.3 quarters 10-QJun 30, 2026
Lipocine4,979190(3,028)*8.2M7.7 quarters 10-QJun 30, 2026
Akari Therapeutics7,694not reported(3,109)*155.8B2.5 quarters 10-QJun 30, 2026
X4 Pharmaceuticals195,0952,400(20,788)*99.1M9.4 quarters 10-QJun 30, 2026
Marker Therapeutics11,331not reported(3,716)*16.7M3.0 quarters 10-QJun 30, 2026
Ernexa Therapeutics5,028not reported(4,152)*1.6M1.2 quarters 10-QJun 30, 2026
Edesa Biotech10,300not reported(3,083)*9.6M3.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.